Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C5731005 Phase 2 Basket Study of Disitamab Vedotin in HER2-Expressing Solid Tumors
2023-504445-31-00Phase 2Authorised
- Sponsor
- Seagen Inc.
- Start
- Sep 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in head and neck cancer (HNC), non-small cell lung cancer (NSCLC), Ovarian Epithelial Adenocarcinoma and 3 more, sponsored by Seagen Inc. Primary endpoint: Confirmed objective response rate (ORR) per RECIST v1.1. Planned start Sep 2024; status: authorised.
02
Drugs
disitamab vedotin
03
Conditions
head and neck cancer (HNC)non-small cell lung cancer (NSCLC)Ovarian Epithelial Adenocarcinomafallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2023-504445-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504445-31-00.